Refractory Lupus Nephritis (RLN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Refractory Lupus Nephritis (RLN) Market Outlook

Thelansis’s “Refractory Lupus Nephritis (RLN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Lupus Nephritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Refractory Lupus Nephritis (RLN) Overview

Lupus nephritis (LN) is a significant and common complication of systemic lupus erythematosus (SLE) that significantly impacts patients' well-being and survival. In adults with SLE, up to 60% experience varying degrees of renal disease during their illness. Despite advances in treatment, including the use of corticosteroids and immunosuppressive drugs like cyclophosphamide (CYP) and mycophenolate mofetil (MMF), a notable percentage of LN patients, ranging from 20% to 70%, do not respond well to standard immunosuppressive therapy. When patients with LN fail to achieve clinical remission after appropriate induction immunosuppressive treatment, it is termed refractory lupus nephritis, significantly raising the risk of advancing to end-stage kidney disease and death. Molecular biomarkers show promise as potential substitutes for kidney biopsies in predicting renal outcomes and long-term prognosis. However, the key factor of medication adherence can distinguish between refractory (or resistant) LN and relapsing LN, with the latter being much more common. Almost half of patients with proliferative LN who initially achieve complete remission with immunosuppressive therapy will experience a relapse or renal flare after reducing or stopping their immunosuppressive medication. Other factors contributing to treatment resistance include genetic predisposition and comorbidities such as hypertension, diabetic nephropathy, and antiphospholipid antibodies, all of which require effective management in the overall care of these patients. Several elements can lead to refractory LN, including issues with medication adherence, tolerability of therapy, and adverse events. Late diagnosis, when irreversible damage has already occurred, is another potential contributor to refractory disease. Geographic, genetic, and other epidemiological factors influence how patients respond to treatment and their renal outcomes, and there is still variability in the initial treatment choices. The EULAR/ERA-EDTA recommendations propose switching from either cyclophosphamide (CYC) to mycophenolate mofetil (MMF) or vice versa in cases of refractory disease.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: